THYNK CAPITAL, LLC.
Thynk Capital possess a historical investment performance in the top 1% of venture capital. Focused on investments in early stage pharma and biotech companies focused on extending HealthSpan and major diseases of Aging including Alzheimer's, Dementia, Kidney Disease, Cancer, Cardiovascular, Diabetes, Frailty, and Rare Disease which affect over 25% of the population and growing at 10%/year.
THYNK CAPITAL, LLC.
Industry:
Biotechnology Health Care
Founded:
2011-03-04
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon WordPress Font Awesome Apache Sitelinks Search Box Microsoft Exchange Online
Similar Organizations
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Nivalis Therapeutics
Nivalis Therapeutics is a clinical-stage pharmaceutical company developing a novel class of disease modifying therapies.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-08-20 | IMX | Thynk Capital, LLC. investment in Seed Round - IMX | N/A |
| 2021-03-05 | iviva medical | Thynk Capital, LLC. investment in Seed Round - iviva medical | N/A |
| 2019-05-30 | Viscient Biosciences | Thynk Capital, LLC. investment in Seed Round - Viscient Biosciences | N/A |
| 2019-05-07 | Repair Biotechnologies | Thynk Capital, LLC. investment in Seed Round - Repair Biotechnologies | 2.15 M USD |
| 2019-04-05 | X-Vax Technology | Thynk Capital, LLC. investment in Series A - X-Vax Technology | N/A |
| 2019-04-01 | Repair Biotechnologies | Thynk Capital, LLC. investment in Convertible Note - Repair Biotechnologies | N/A |
| 2018-11-06 | Elicio Therapeutics | Thynk Capital, LLC. investment in Venture Round - Elicio Therapeutics | N/A |
| 2018-06-25 | KitoTech Medical | Thynk Capital, LLC. investment in Convertible Note - KitoTech Medical | N/A |
| 2018-03-22 | Marina Biotech | Thynk Capital, LLC. investment in Post-IPO Equity - Marina Biotech | N/A |
| 2018-02-20 | Elevian | Thynk Capital, LLC. investment in Convertible Note - Elevian | 2.9 M USD |